{
  "id": 810377,
  "title": "Earnings call transcript: Kyntra Bio rises as pipeline updates offset weak Q2 2026 sales",
  "url": "https://urgent.news/2026/08/13/earnings-call-transcript-kyntra-bio-rises-as-pipeline-updates-offset",
  "topic": "finance",
  "section": "Finance & Markets",
  "published": "2026-08-13T22:03:52.000Z",
  "source": {
    "name": "Investing.com",
    "slug": "investing-com",
    "url": "https://www.investing.com/news/transcripts/earnings-call-transcript-kyntra-bio-rises-as-pipeline-updates-offset-weak-q2-2026-sales-93CH-4859457"
  },
  "original_language": "en",
  "account": "Kyntra Bio reported mixed second-quarter results on an earnings call. Revenue turned negative to $1.5 million, down from $1.3 million a year earlier, while net income improved to $12 million, or $2.96 per share, compared with a loss of $13.7 million, or $3.38 per share. Operating expenses increased 20% to $16.1 million, with research and development spending up 15.3% to $6.8 million and selling, general and administrative expenses rising 31% to $9.3 million. The company has $95.7 million in cash, investments and receivables, with a cash runway extending into 2028. Key clinical programs include FG-3246, a CD46-targeted prostate cancer therapy on track for Phase II interim analysis in Q4 2026, and roxadustat, an oral treatment for lower-risk myelodysplastic syndromes moving toward a Phase III start in Q4 2026. Management emphasized the company's strong balance sheet and pipeline progress despite the weak operating results, stating that the profit was likely driven by non-operating items rather than core business strength.",
  "summary": null,
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 2,
    "also_reported_by": [
      {
        "outlet": "Investing.com",
        "title": "Earnings call transcript: STAAR Surgical tops revenue views in Q2 2026",
        "url": "https://urgent.news/2026/08/12/earnings-call-transcript-staar-surgical-tops-revenue-views-in-q2-2026",
        "published": "2026-08-12T22:31:44.000Z"
      }
    ]
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}